Merrimack Pharmaceuticals (NASDAQ:MACK) Director Gary Crocker purchased 4,400 shares of the stock in a transaction dated Wednesday, May 7th. The shares were purchased at an average cost of $6.77 per share, with a total value of $29,788.00. Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) weekly performance is 3.89%. On last trading day company shares ended up $6.68. Analysts mean target price for the company is $10.90. Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) distance from 50-day simple moving average (SMA50) is 25.48%.
Aegerion Pharmaceuticals (NASDAQ:AEGR) Director Anne Vanlent purchased 4,000 shares of the stock in a transaction that occurred on Thursday, May 8th. The shares were purchased at an average cost of $33.78 per share, with a total value of $135,120.00. Following the transaction, the director now directly owns 4,000 shares of the company’s stock, valued at approximately $135,120. Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) shares fell -1.12% in last trading session and ended the day on $32.62. AEGR gross Margin is 89.70% and its return on assets is -45.10%.Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) quarterly performance is -47.53%.
Opko Health (NYSE:OPK) CEO Phillip Md Et Al Frost bought 73,900 shares of the company’s stock in a transaction that occurred on Thursday, May 8th. The shares were purchased at an average cost of $8.06 per share, with a total value of $595,634.00. Following the completion of the transaction, the chief executive officer now directly owns 1,987,500 shares of the company’s stock, valued at approximately $16,019,250. Opko Health Inc. (NYSE:OPK) shares moved up 2.87% in last trading session and was closed at $8.24, while trading in range of $7.90 – $8.25. Opko Health Inc. (NYSE:OPK) year to date (YTD) performance is -2.37%.
AtriCure (NASDAQ:ATRC) SVP Douglas Seith purchased 1,000 shares of the stock on the open market in a transaction dated Tuesday, May 6th. The stock was purchased at an average price of $15.04 per share, with a total value of $15,040.00. Following the completion of the transaction, the senior vice president now directly owns 95,694 shares of the company’s stock, valued at approximately $1,439,238. AtriCure Inc. (NASDAQ:ATRC) ended the last trading day at $15.44. Company weekly volatility is calculated as 6.59% and price to cash ratio as 5.33.AtriCure Inc. (NASDAQ:ATRC) showed a positive weekly performance of 2.12%.